The journey from vitamin D-resistant rickets to the regulation of renal phosphate transport

Clinical Journal of the American Society of Nephrology

Volumn 4, Issue 11, 2009, Pages 1866-1877

  Levine, Barton S ^a   Kleeman, Charles R ^a   Felsenfeld, Arnold J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHATE; PROTEINASE; VITAMIN D;

ALBRIGHT SYNDROME; DRUG MECHANISM; DRUG MEGADOSE; GENE INTERACTION; GENETIC DISORDER; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; HYPOPHOSPHATEMIA; KIDNEY TUBULE ABSORPTION; MINERAL METABOLISM; NONHUMAN; PARATHYROID HORMONE BLOOD LEVEL; PATHOPHYSIOLOGY; PHOSPHATE METABOLISM; PHOSPHATE TRANSPORT; PROTEIN ANALYSIS; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; SEQUENCE HOMOLOGY; VITAMIN D METABOLISM; X CHROMOSOME; X LINKED HYPOPHOSPHATEMIC RICKETS;

FIBROUS DYSPLASIA, POLYOSTOTIC; HUMANS; HYPOPHOSPHATEMIC RICKETS, X-LINKED DOMINANT; KIDNEY; PHOSPHATES;

EID: 73449111575     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.03000509     Document Type: Review

References (110)

1. Albright F, Burnett CH, Smith PH: Pseudohypoparathyroidism: An example of "Seabright-Bantam syndrome." Endocrinology 30: 922-932, 1942
2. Albright F, Butler AM, Bloomberg E: Rickets resistant to vitamin D therapy. Am J Dis Child 54: 529-547, 1937
3. Albright F, Butler AM, Hampton AO, Smith P: Syndrome characterized by osteitis fibrosa disseminata, areas of pigmentation and endocrine dysfunction with precocious puberty in females. N Engl J Med 216: 727-746, 1937
4. Scriver CR, Tenenhouse HS, Glorieux F: X-linked hypophosphatemia: An appreciation of a classic paper and a survey of progress since 1958. Medicine 70: 218-228, 1991
5. Winters RW, Graham JB, Williams TF, McFalls VW, Burnett CH: A genetic study of familial hypophosphatemia and vitamin D resistant rickets with a review of the literature. Medicine 37: 97-143, 1958
6. Albright F, Sulkowitch HW: The effect of vitamin D on calcium and phosphorus metabolism: Studies on four patients. J Clin Invest 7: 305-315, 1938
7. Bacic D, Lehir M, Biber J, Kaissling B, Murer H, Wagner CA: The renal Na+/phosphate cotransporter NaPi-IIa is internalized via the receptor-mediated endocytic route in response to parathyroid hormone. Kidney Int 69: 495-503, 2006
8. Tenenhouse HS: X-linked hypophosphataemia: A homologous disorder in humans and mice. Nephrol Dial Transplant 14: 14-22, 1999
9. Collins JF, Ghishan FK: The molecular defect in the renal sodium-phosphate transporter expression pathway of Gyro (Gy) mice is distinct from that of hypophosphatemic (Hyp) mice. FASEB J 10: 751-759, 1996
10. Meyer Jr. RA, Meyeer MH, Gray RW: Parabiosis suggests a humoral factor is involved in X-linked hypophosphatemia. J Bone Miner Res 4: 493-500, 1989
11. Meyer RA Jr, Tenenhouse H, Meyer MH, Klugerman AH: The renal phosphate transport defect in normal mice parabiosed to X-linked hypophosphatemic mice persists after parathyroidectomy. J Bone Miner Res 4: 523-532, 1989
12. Nesbitt T, Coffman TM, Griffiths R, Drezner MK: Crosstransplantation of kidneys in normal and Hyp mice: Evidence that the Hyp mouse phenotype is unrelated to an intrinsic renal defect. J Clin Invest 89: 1453-1459, 1992
13. Lajeunesse D, Meyer RA Jr, Hamel L: Direct demonstration of a humorally-mediated inhibition of renal phosphate transport in the Hyp mouse. Kidney Int 50: 1531-1538, 1996
14. Kos CH, Tihy F, Econs MJ, Murer H, Lemieux N, Tenenhouse HS: Localization of a renal sodium phosphate cotransporter gene to human chromosome 5q35. Genomics 19: 176-177, 1994
15. Soumounou Y, Gauthier C, Tenenhouse HS: Murine and human type I Na-phosphate cotransporter genes: Structure and promoter activity. Am J Physiol Renal Physiol 281: F1082-F1091, 2001
16. Bergwitz C, Roslin NM, Tieder M, Loredo-Osti C, Bastepe M, Abu-Zahra H, Frappier D, Burkett K, Carpenter TO, Anderson D, Garabedian M, Sermet I, Fujiwara TM, Morgan K, Tenenhouse HS, Juppner H: SLC34A3 mutations in patients with hereditary hypophosphatemic rickets with hypercalciuria predict a key role for the sodium-phosphate cotransporter NaPi-IIc in maintaining phosphate homeostasis. Am J Hum Genet 78: 179-192, 2006
17. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Thy Hyp Consortium. Nat Genet 11: 130-136, 1995
18. Rowe PS: The wrickkended pathways of FGF23, MEPE and PHEX. Crit Rev Oral Biol Med 15: 264-281, 2004
19. Imel EA, Econs MJ: Fibroblast growth factor 23: Roles in health and disease. J Am Soc Nephrol 16: 2565-2575, 2005
20. Bai XY, Miao D, Goltzman D, Karaplis AC: Partial rescue of the Hyp phenotype by osteoblast-targeted PHEX (phosphate-regulating gene with homologies to endopeptidases on the X chromosome) expression. Mol Endocrinol 16: 2913-2925, 2002
21. Erben RG, Mayer D, Weber K, Jonsson K, Juppner H, Lanske B: Overexpression of human PHEX under the human β-actin promoter does not fully rescue the HYP mouse phenotype. J Bone Miner Res 20: 1149-1160, 2005
22. Mulroney SE, Woda CB, Halaihel N, Louie B, McDonnell K, Schulkin J, Haramati A, Levi M: Central control of renal sodium-phosphate (NaPi-2) transporters. Am J Physiol Renal Physiol 286: F647-F652, 2004
23. Yuan B, Takaiwa M, Clemens TL, Feng JQ, Kumar R, Rowe PS, Xie Y, Drezner MK: Aberrant Phex function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemia. J Clin Invest 118: 722-734, 2008
24. Bianchine J, Stambler A, Harrison H: Familial hypophosphatemic rickets showing autosomal dominant inheritance. Birth Defects Orig Artic Ser 7: 287-294, 1971
25. ADHR Consortium: Autosomal dominant hypophosphatemic rickets is associated with mutations in FGF23. Nat Genet 26: 345-348, 2000
26. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T: FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19: 429-435, 2004
27. Shimada T, Yamazaki Y, Takahashi M, Hasegawa H, Urakawa I, Oshima T, Ono K, Kaktani M, Tomizuka K, Fujita T, Fukumoto S, Yamashita T: Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol 289: F1088-F1095, 2005
28. White KD, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ: Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 60: 2079-2086, 2001
29. Shimada T, Muto T, Urakawa I, Yoneya T, Yamazaki Y, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T: Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and enhances in vivo biological potency. Endocrinology 143: 3179-3182, 2002
30. Bai XY, Miao D, Goltzman D, Karaplis AC: The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem 278: 9843-9849, 2003
31. Weber TJ, Liu S, Indridason OS, Quarles LD: Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res 18: 1227-1234, 2003
32. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda E, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T: Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A 98: 6500-6505, 2001
33. Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Juppner H: Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348: 1656-1663, 2003
34. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S: Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87: 4957-4960, 2002
35. Sitara D, Razzaque MS, Hesse M, Yganathan S, Taguchi T, Erben RG, Juppner H, Lanske B: Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol 23: 421-432, 2004
36. Liu S, Zhou J, Tang W, Jiang X, Rowe DW, Quarles LD: Pathogenic role of FGF23 in Hyp mice. Am J Physiol Endocrinol Metab 291: E38-E49, 2006
37. Aono Y, Yamakazi Y, Yasutake J, Kawata T, Hasegawa H, Urakawa I, Fujita T, Wada M, Yamashita T, Fukumoto S, Shimada T: The neutralization of FGF-23 ameliorates hypophosphatemia and rickets in Hyp mice [Abstract]. J Bone Miner Res 18: S16, 2003
38. Bowe AE, Finnegan R, Jan de Beur SM, Cho J, Levine MA, Kumar R, Schiavi SC: FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun 284: 977-981, 2001
39. Benet-Pages A, Lorenz-Depiereux B, Zischka H, White KE, Econs MJ, Strom TM: FGF23 is processed by proprotein convertases but not by PHEX. Bone 35: 455-462, 2004
40. Liu S, Guo R, Simpson LG, Xiao ZS, Burnham CE, Quarles LD: Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem 278: 37419-37426, 2007
41. Campos M, Couture C, Hirata IY, Juliano MA, Loisel TP, Crine P, Juliano L, Boileau G, Carmona AK: Human recombinant PHEX has a strict S1′ specificity for acidic residues and cleaves peptides derived from FGF-23 and MEPE. Biochem J 373: 271-279, 2003
42. Strom TM, Juppner H: PHEX, FGF23, DMP1 and beyond. Curr Opin Nephrol Hypertens 17: 357-362, 2008
43. Mirams M, Robinson BG, Mason RS, Nelson AE: Bone as a source of FGF23: Regulation by phosphate? Bone 35: 1192-1199, 2004
44. Sitara D, Kim S, Razzaque MS, Bergwitz C, Taguchi T, Schuler C, Erben RG, Lanske B: Genetic evidence of serum phosphate-independent functions of FGF-23 on bone. PLoS Genet 4: e1000154, 2008
45. Quarles LD: FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization. Am J Physiol Endocrinol Metab 285: E1-E9, 2003
46. Rowe PS, deZoysa P, Dong R, Wang H, White KD, Econs MJ: MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone 34: 303-319, 2004
47. Jain A, Fedarko NS, Collins MT, Gelman R, Ankrom MA, Tayback M, Fisher LW: Serum levels of matrix extracellular phosphoglycoprotein (MEPE) in normal humans correlate with serum phosphorus, parathyroid hormone and bone mineral density. J Clin Endocrinol Metab 89: 4158-4161, 2004
48. Marks J, Churchill LJ, Debnam ES, Unwin RJ: Matrix extracellular phosphoglycoprotein inhibits phosphate transport. J Am Soc Nephrol 19: 2313-2320, 2008
49. Allen HD, Fedarko NS, Jain A, Whybro A, Barker ME, Eastell R, Blumsohn A: The response of MEPE to long-term and short-term phosphate supplementation in healthy volunteers [Abstract]. J Bone Miner Res 18: S170, 2003
50. Argiro L, Desbarats M, Glorieux FH, Escarot B: Mepe, the gene encoding a tumor-secreted protein in oncogenic hypophosphatemic osteomalacia, is expressed in bone. Genomics 74: 342-351, 2001
51. Liu S, Brown TA, Zhou J, Xiao ZS, Awad H, Guilak F, Quarles LD: Role of matrix extracellular phosphoglycoprotein in the pathogenesis of X-linked hypophosphatemia. J Am Soc Nephrol 16: 1645-1653, 2005
52. Kolek OI, Hines ER, Jones MD, LeSueur LK, Lipko MA, Kiela PR, Collins JF, Haussler MR, Gishan FK: 1α,25-Dihydroxyvitamin D3 upregulates FGF23 gene expression in bone: The final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am J Physiol Gastrointest Liver Physiol 289: G1036-G1042, 2005
53. Liu S, Tang W, Zhou J, Stubbs JH, Luo Q, Pi M, Quarles LD: FGF23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 17: 1305-1315, 2006
54. Ito M, Sakai Y, Furumoto M, Segawa H, Haito S, Yamanaka S, Nakamura R, Kuwahata M, Miyamoto KI: Vitamin D and phosphate regulate fibroblast growth factor-23 in K-562 cells. Am J Physiol Endocrinol Metab 288: E1101-E1109, 2005
55. Miyamoto K, Ito M, Kuwahata M, Kato S, Segawa H: Inhibition of intestinal sodium-dependent inorganic phosphate transport by fibroblast growth factor 23. Ther Apher Dial 9: 331-335, 2005
56. Herrell RM, Lyles KW, Harrelson JM, Friedman NE, Drezner MK: Healing of bone disease in X-linked hypophosphatemic rickets/osteomalacia: Induction and maintenance with phosphorus and calcitriol. J Clin Invest 75: 1858-1868, 1985
57. Arnaud C, Glorieux F, Scriver CR: Serum parathyroid hormone in X-linked hypophosphatemia. Science 173: 845-847, 1971
58. Lewy JE, Cabana EC, Repetto HA, Canterbury JM, Reiss E: Serum parathyroid hormone in hypophosphatemic vitamin D-resistant rickets. J Pediatr 81: 294-300, 1972
59. Kiebzak GM, Meyer RA Jr: X-linked hypophosphatemic mice are not hypersensitive to parathyroid hormone. Endocrinology 110: 1030-1036, 1982
60. Meyer RA Jr, Meyer MH, Gray RW: Parabiosis suggests a humoral factor is involved in X-linked hypophosphatemia in mice. J Bone Miner Res 4: 493-500, 1989
61. Blydt-Hansen T, Tenenhouse H, Goodyer P: PHEX expression in parathyroid gland and parathyroid hormone dysregulation in X-linked hypophosphatemia. Pediatr Nephrol 13: 607-611, 1999
62. Schmitt C, Mehls O: The enigma of hyperparathyroidism in hypophosphatemic rickets. Pediatr Nephrol 19: 473-477, 2004
63. Larsson T, Marsell R, Schipani E, Ohlsson C, Ljunggren O, Tenenhouse HS, Juppner H, Jonsson K: Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1 (I) collagen promoter exhibit growth retardation, osteomalacia and disturbed phosphate homeostasis. Endocrinology 145: 3087-3094, 2007
64. Bai XY, Miao D, Li J, Goltzman D, Karaplis AC: Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting. Endocrinology 145: 5269-5279, 2004
65. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-o M, Mohammadi M, Sirkis R, Naveh-Many T, Silver J: The parathyroid is a target organ for FGF23 in rats. J Clin Invest 117: 4003-4008, 2007
66. Felsenfeld AJ, Rodriguez M: Phosphorus, regulation of plasma calcium and secondary hyperparathyroidism: A hypothesis to integrate a historical and modern perspective. J Am Soc Nephrol 10: 878-890, 1999
67. Rodriguez M, Felsenfeld AJ, Llach F: Calcemic response to parathyroid hormone in renal failure: Role of calcitriol and the effect of parathyroidectomy. Kidney Int 40: 1063-1068, 1991
68. Ishii H, Wada M, Furuya Y, Nagano N, Nemeth EF, Fox J: Daily intermittent decreases in serum levels of parathyroid hormone have an anabolic-like action on the bones of uremic rats with low-turnover bone and osteomalacia. Bone 26: 175-182, 2000
69. Hoag LA, Rivkin H, Weigele CE, Berliner F: Effect of potent parathyroid extract on calcium balance in infants. Am J Dis Child 33: 910, 1927
70. Morgan AF: Effect of diet on response to parathyroid extract and vitamin D: IV. The effect of diets of normal calcium and phosphorus content in dogs. Am J Physiol 105: 621-634, 1933
71. Xiao ZS, Crenshaw M, Guo R, Nesbitt T, Drezner MK, Quarles LD: Intrinsic mineralization defect in Hyp mouse osteoblasts. Am J Physiol Endocrinol Metab 275: E700-E708, 1998
72. Nesbitt T, Drezner MK, Lobaugh B: Abnormal parathyroid hormone stimulation of 25-hydroxyvitamin D-1-alpha-hydroxylase activity in the hypophosphatemic mouse: Evidence for generalized defect of vitamin D metabolism. J Clin Invest 77: 181-187, 1986
73. Fujiwara I, Aravindan R, Horst RL, Drezner MK: Abnormal regulation of renal 25-hydroxyvitamin D-1alpha-hydroxylase activity in X-linked hypophosphatemia: A translational or post-translational defect. J Bone Miner Res 18: 434-442, 2003
74. Eisenberg E: Effects of serum calcium level and parathyroid extracts on phosphate and calcium excretion in hypoparathyroid patients. J Clin Invest 44: 942-946, 1965
75. Yamashita H, Yamazaki Y, Hasegawa H, Yamashita T, Fukumoto S, Shigematsu T, Kazama JJ, Fukagawa M, Noguchi S: Fibroblast growth factor-23 (FGF23) in patients with transient hypoparathyroidism: Its important role in serum phosphate regulation. Endocrine J 54: 465-470, 2007
76. Ferrari SL, Bonjour J-P, Rizzoli R: Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 90: 1519-1524, 2006
77. Nagano N, Miyata S, Abe M, Kobayashi N, Wakita S, Yamashita T, Wada M: Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats. Kidney Int 69: 531-537, 2006
78. Glorieux FH, Scriver CR, Reade TM, Goldman H, Roseborough A: Use of phosphate and vitamin D to prevent dwarfism and rickets in X-linked hypophosphatemia. N Engl J Med 287: 481-487, 1972
79. Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, White KE, Waguespack S, Gupta A, Hannon T, Econs MJ, Bianco P, Robey PG: FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 112: 683-692, 2003
80. Fukagawa M, Nii-Kono T, Kazama JJ: Role of fibroblast growth factor 23 in health and in chronic kidney disease. Curr Opin Nephrol Hypertens 14: 325-329, 2005
81. Perwad F, Azam N, Zhang MY, Yamashita T, Tenenhouse HS, Portale AA: Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology 146: 5358-5364, 2005
82. Nishida Y, Taketani Y, Yamanaka-Okumura H, Imamura F, Taniguchi A, Sato T, Shuto E, Nashiki K, Arai H, Yamamoto H, Takeda E: Acute effect of oral phosphate loading on serum fibroblast growth factor 23 levels in healthy men. Kidney Int 70: 2141-2147, 2006
83. Isakova T, Guitierrez O, Shah A, Castaldo L, Holmes J, Lee H, Wolf M: Postprandial mineral metabolism and secondary hyperparathyroidism in early CKD. J Am Soc Nephrol 19: 615-623, 2008
84. Yamazaki Y, Tamada T, Kasai N, Urakawa I, Aono Y, Hasegawa H, Fujita T, Kuroki R, Yamashita T, Fukumoto S, Shimada T: Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J Bone Miner Res 23: 1509-1518, 2008
85. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB: Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 64: 2272-2279, 2003
86. Sato T, Ohta M, Kawaguchi Y, Okada H, Ono M, Saito H, Utsunomiya M, Tamura T, Sugimoto K, Takamizawa S, Tanaka H, Shigematsue T, Tojo K, Sakai O: Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism. Am J Kidney Dis 44: 481-487, 2004
87. Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Juppner H, Wolf M: Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 16: 2205-2215, 2005
88. Bhan I, Shah A, Holmes J, Isakova T, Guitierrez O, Burnett S-A, Juppner H, Wolf M: Post-transplant hypophosphatemia: Tertiary "hyper- phosphatoninism"? Kidney Int 70: 1486-1494, 2006
89. Rendina D, Mossetti G, De Filippo G, Cioffi M, Strazzullo P: Fibroblast growth factor 23 is increased in calcium nephrolithiasis with hypophosphatemia and renal phosphate leak. J Clin Endocrinol Metab 91: 959-963, 2006
90. Liu S, Vierthaler L, Tang W, Zhou J, Quarles LD: FGFR3 and FGFR4 do not mediate renal effects of FGF23. J Am Soc Nephrol 19: 2342-2350, 2008
91. Kuro-o M: Klotho as a regulator of fibroblast growth factor signaling and phosphate/calcium metabolism. Curr Opin Nephrol Hypertens 15: 437-441, 2006
92. Yu X, Sabbagh Y, Davis SI, Demay MB, White KE: Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology 146: 4647-4656, 2002
93. White KE, Cabral JM, Davis SI, Fishburn T, Evans WE, Ichikawa S, Fields J, Yu X, Shaw NJ, McLellan NJ, McKeown C, Fitzpatrick D, Yu K, Ornitz DM, Econs MJ: Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation. Am J Hum Genet 76: 361-367, 2004
94. Evans WE, Ichikawa S, Davis SI, Econs MJ: A missense mutation in FGFR1 causes a novel syndrome: Craniofacial dysplasia with hypophosphatemia. J Bone Miner Res 18[Suppl 2]: S4, 2003
95. Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt K, Baum MG, Schiavi S, Hu M-C, Moe OW, Kuro-o M: Regulation of fibroblast growth factor-23 signaling by Klotho. J Biol Chem 281: 6120-6123, 2006
96. Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T: Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444: 770-774, 2006
97. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima Y: Mutation of the klotho gene leads to a syndrome resembling ageing. Nature 390: 45-51, 1997
98. Razzaque MS, Lanske B: Hypervitaminosis D and premature aging: Lessons learned from FGF23 and Klotho mutant mice. Trends Mol Med 12: 298-305, 2006
99. Segawa H, Yamanaka S, Ohno Y, Onitsuka A, Shiozawa K, Aranami F, Furutani J, Tomoe Y, Ito M, Kuwahata M, Tatsumi S, Imura A, Nabeshima Y, Miyamoto K-I: Correlation between hyperphosphatemia and type II Na/Pi cotransporter activity in klotho mice. Am J Physiol Renal Physiol 292: F769-F779, 2007
100. Farrow G, Davis SI, Summers LJ, White KE: Initial FGF23-mediated signaling occurs in the distal convoluted tubule. J Am Soc Nephrol 20: 955-960, 2009
101. Morishita K, Shirai A, Kubota M, Katakura Y, Nabeshima YI, Takeshige K, Kamiya T: The progression of aging in Klotho mutant mice can be modified by dietary phosphorus and zinc. J Nutr 131: 3182-3188, 2001
102. Eicher EM, Southard JL, Scriver CR, Glorieux F: Hypophosphatemia: Mouse model for human familial hypophosphatemic (vitamin D-resistant) rickets. Proc Natl Acad Sci U S A 73: 4667-4671, 1976
103. Morgan JM, Hawley WL, Chenoweth AI, Retan WJ, Diethelm AG: Renal transplantation in hypophosphatemia with vitamin D-resistant rickets. Arch Intern Med 134: 549-552, 1974
104. Lyles KW, Clark AG, Drezner MK: Serum 1,25-dihydroxyvitamin D levels in subjects with X-linked hypophosphatemic rickets and osteomalacia. Calcif Tissue Int 34: 125-130, 1982
105. Posillico JT, Lobaugh BP, Muhlbaier LH, Drezner MK: Abnormal parathyroid function in the X-linked hypophosphatemic mouse. Calcif Tissue Int 37: 418-422, 1985
106. Lipman ML, Panda D, Bennett HP, Henderson JE, Shane E, Shen Y, Goltzman D, Karaplis AC: Cloning of human Pex cDNA: Expression, subcellular localization, and endopeptidase activity. J Biol Chem 273: 13729-13737, 1998
107. Brewer A, Canaff L, Hendy GN, Tenenhouse HS: Differential regulation of PHEX expression in bone and parathyroid gland by chronic renal insufficiency and 1,25-dihydroxyvitamin D3. Am J Physiol Renal Physiol 286: F739-F748, 2004
108. Krajisnik T, Björland P, Marsell R, Ljunggren O, Akerstrom G, Jonsson KB, Westin G, Larsson TE: Fibroblast growth factor-23 regulates parathyroid hormone and 1α-hydroxylase in cultured bovine parathyroid cells. J Endocrinol 195: 125-131, 2007
109. Silver J, Naveh-Many T: Phosphate and the parathyroid. Kidney Int 75: 898-905, 2009
110. Albright F, Reifenstein EC Jr: Parathyroid Glands and Metabolic Bone Disease, Selected Studies, Baltimore, Williams & Wilkins, 1948, p. 222